文献速递胃肠动力与功能性疾病

抗痉挛药治疗慢性腹痛:北美治疗选择分析

Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

本文综述了北美可用的抗痉挛药(如阿尔维林、双环维林、东莨菪碱、莨菪碱、美贝维林、奥替溴铵、匹维溴铵和曲美布汀)治疗常见肠-脑互动障碍患者慢性腹痛的疗效与安全性。因研究在剂量、疗程、患者特征和诊断标准上不一致,且终点变异大、偏倚风险多为「不清楚」,各药疗效与安全性差异显著,应个体化选择而非按类别用药。

要点

  • 抗痉挛药涵盖抗胆碱能、钙通道抑制剂和直接平滑肌松弛剂等不同机制类别。
  • 各药疗效与安全性差异显著,应基于个体药物证据而非类别整体信息选择。
  • 研究间剂量、疗程、患者特征和诊断标准不一致,限制比较。

核心结论

  • 抗痉挛药治疗慢性腹痛的疗效与安全性因药物而异,应个体化考虑每种药物而非按类别处方。

研究设计与样本

  • 综述文章,旨在评估北美可用抗痉挛药治疗常见肠-脑互动障碍患者慢性腹痛的疗效与安全性。

主要发现

  • 所评估的抗痉挛药在疗效和安全性方面差异显著。
  • 研究间在治疗剂量、疗程、患者特征和诊断标准上存在不一致,限制了比较。
  • 研究终点变异大,且选择、实施、检测、失访和报告偏倚风险各异,许多情况下风险被评为「不清楚」。

临床怎么用

  • 临床应基于每种药物的个体证据选择抗痉挛药,而非依据整个类别的信息处方。

局限性

  • 研究间剂量、疗程、患者特征和诊断标准不一致,终点变异大,偏倚风险多为「不清楚」。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic abdominal pain is a common gastrointestinal (GI) symptom that characterizes many functional GI disorders/disorders of gut-brain interaction, including irritable bowel syndrome, functional dyspepsia, and centrally mediated abdominal pain syndrome. The symptoms of abdominal pain in these highly prevalent disorders are often treated with antispasmodic agents. Antispasmodic treatment includes a broad range of therapeutic classes with different mechanisms of action, including anticholinergic/antimuscarinic agents (inhibition of GI smooth muscle contraction), calcium channel inhibitors (inhibition of calcium transport into GI smooth muscle), and direct smooth muscle relaxants (inhibition of sodium and calcium transport). The aim of this review article was to examine the efficacy and safety of antispasmodics available in North America (e.g., alverine, dicyclomine, hyoscine, hyoscyamine, mebeverine, otilonium, pinaverium, and trimebutine) for the treatment of chronic abdominal pain in patients with common disorders of gut-brain interaction. For the agents examined, comparisons of studies are limited by inconsistencies in treatment dosing and duration, patient profiles, and diagnostic criteria employed. Furthermore, variability in study end points limits comparisons. Risk of selection, performance, detection, attrition, and reporting bias also differed among studies, and in many cases, risks were considered "unclear." The antispasmodics evaluated in this review, which differ in geographic availability, were found to vary dramatically in efficacy and safety. Given these caveats, each agent should be considered on an individual basis, rather than prescribed based on information across the broad class of agents.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Brenner DM, Lacy BE. Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options. Am J Gastroenterol. 2021. PMID: 33993133. doi:10.14309/ajg.0000000000001266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。